Eplontersen,Inotersen
Ionis Pharmaceuticals,Akcea Therapeutics,Astrazeneca
[]
dcbn news: neuro-ttransform phase iii results presented at aan showed eplontersen demonstrated consistent and sustained improvement in all measures of disease and quality of life through 66 weeks: wilmington, ... #biotech #news 
Life science news and jobs from Washington DC, Maryland and Virginia. Part of @BiotechNetworks, connecting #biotech since 2008.